

**AMENDMENTS TO THE SPECIFICATION:**

*Please replace the paragraph starting at page 1, line 11 with the paragraph set forth below.*

Cell lines derived from chronic lymphocytic leukemia (CLL) cells and the uses thereof in the study and treatment of CLL and other diseases are disclosed. In particular, this disclosure relates to a CLL cell line designated "CLL-AAT", deposited on ~~November 28~~ December 11, 2001 with the American Type Culture Collection (Manassas, Virginia, USA) in accordance with the terms of the Budapest Treaty under ATCC accession no. PTA-3920.

*Please replace the paragraph starting at page 7, line 10 with the paragraph set forth below. Applicants note that paragraph set forth below represents the text of the paragraph as amended by the preliminary amendment filed on August 23, 2005.*

Figs. 9A-9C provide a summary of CDR sequences and binding specificities of selected scFv antibodies. As shown in Figure 9B, the clone numbers listed in the left column are also referred to herein by scFv numbers as follows: A2c (scFv-1), G12.1c (scFv-2), B4.2a (scFv-17), E1c (scFv-3), F2d (scFv-18), E5e (scFv-4), H6.2b (scFv-5), G10.1 (scFv-19), D11.1c (scFv-6), A5.2c (scFv-20), F1d (scFv-7), F1e (scFv-8), E4.2 (scFv-21), E2c (scFv-9), A9c (scFv-9), E11e (scFv-10), A1.1 (scFv-11), F5.2 (scFv-12), F10b (scFv-22), F7a (scFv-23), F6b (scFv-13), C12b (scFv-24), D2.1b (scFv-14), D1.1 (scFv-25), D2.2a (scFv-15), and D2.2b (scFv-16).